相似文献
1
PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
Cancer Lett. 2008 Oct 18;270(1):10-8. doi: 10.1016/j.canlet.2008.03.035. Epub 2008 May 23.
2
JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Oncogene. 2014 Feb 27;33(9):1148-57. doi: 10.1038/onc.2013.46. Epub 2013 Feb 25.
3
Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
J Pathol. 2007 Jun;212(2):143-51. doi: 10.1002/path.2170.
4
PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Oncogene. 2018 Apr;37(15):1991-2007. doi: 10.1038/s41388-017-0081-3. Epub 2018 Jan 25.
5
Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
Sci Transl Med. 2022 Jul 13;14(653):eabq2096. doi: 10.1126/scitranslmed.abq2096.
6
Classification of rhabdomyosarcoma and its molecular basis.
Adv Anat Pathol. 2013 Nov;20(6):387-97. doi: 10.1097/PAP.0b013e3182a92d0d.
7
The PAX3-FOXO1 fusion protein present in rhabdomyosarcoma interferes with normal FOXO activity and the TGF-β pathway.
PLoS One. 2015 Mar 25;10(3):e0121474. doi: 10.1371/journal.pone.0121474. eCollection 2015.
8
Prognostic factors in patients with localized and metastatic alveolar rhabdomyosarcoma. A report from two studies and two registries of the Cooperative Weichteilsarkom Studiengruppe CWS.
Cancer Med. 2025 Jan;14(1):e70215. doi: 10.1002/cam4.70215.
9
PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
J Pathol. 2017 Apr;241(5):626-637. doi: 10.1002/path.4867. Epub 2017 Mar 1.
10
Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
Genes Chromosomes Cancer. 2010 Mar;49(3):224-36. doi: 10.1002/gcc.20731.
引用本文的文献
1
Prevalence of locoregional and distant lymph node metastases in children and adolescents/young adults with soft tissue sarcomas: a Bayesian meta-analysis of proportions.
EClinicalMedicine. 2025 Aug 7;87:103390. doi: 10.1016/j.eclinm.2025.103390. eCollection 2025 Sep.
2
RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma.
bioRxiv. 2025 Jul 24:2025.07.21.665972. doi: 10.1101/2025.07.21.665972.
3
Rhabdomyosarcoma fusion oncoprotein initially pioneers a neural signature in vivo.
Cell Rep. 2025 Jul 22;44(7):115923. doi: 10.1016/j.celrep.2025.115923. Epub 2025 Jul 3.
4
Fusion oncogenes in rhabdomyosarcoma: model systems, mechanisms of tumorigenesis, and therapeutic implications.
Front Oncol. 2025 Jun 17;15:1570070. doi: 10.3389/fonc.2025.1570070. eCollection 2025.
5
Fusion genes in cancers: Biogenesis, functions, and therapeutic implications.
Genes Dis. 2025 Jan 20;12(5):101536. doi: 10.1016/j.gendis.2025.101536. eCollection 2025 Sep.
6
Molecular Targets in Alveolar Rhabdomyosarcoma: A Narrative Review of Progress and Pitfalls.
Int J Mol Sci. 2025 May 28;26(11):5204. doi: 10.3390/ijms26115204.
7
Tumors and their microenvironments: Learning from pediatric brain pathologies.
Biochim Biophys Acta Rev Cancer. 2025 Jul;1880(3):189328. doi: 10.1016/j.bbcan.2025.189328. Epub 2025 Apr 18.
8
Programmable protein stabilization with language model-derived peptide guides.
Nat Commun. 2025 Apr 15;16(1):3555. doi: 10.1038/s41467-025-58872-6.
9
Oncogenic gene fusions in cancer: from biology to therapy.
Signal Transduct Target Ther. 2025 Apr 14;10(1):111. doi: 10.1038/s41392-025-02161-7.
10
Accurate fusion transcript identification from long- and short-read isoform sequencing at bulk or single-cell resolution.
Genome Res. 2025 Apr 14;35(4):967-986. doi: 10.1101/gr.279200.124.
本文引用的文献
1
Diagnosing and exploiting cancer's addiction to blocks in apoptosis.
Nat Rev Cancer. 2008 Feb;8(2):121-32. doi: 10.1038/nrc2297.
2
Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma.
Biochem Biophys Res Commun. 2008 Jan 18;365(3):568-74. doi: 10.1016/j.bbrc.2007.11.017. Epub 2007 Nov 20.
3
PAX3-FOXO1 controls expression of the p57Kip2 cell-cycle regulator through degradation of EGR1.
Proc Natl Acad Sci U S A. 2007 Nov 13;104(46):18085-90. doi: 10.1073/pnas.0708910104. Epub 2007 Nov 6.
4
The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
Cancer Res. 2007 Jul 15;67(14):6691-9. doi: 10.1158/0008-5472.CAN-06-3210.
5
Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
J Pathol. 2007 Jun;212(2):143-51. doi: 10.1002/path.2170.
6
The p53 family in differentiation and tumorigenesis.
Nat Rev Cancer. 2007 Mar;7(3):165-8. doi: 10.1038/nrc2072. Epub 2007 Feb 1.
7
SP analysis may be used to identify cancer stem cell populations.
Exp Cell Res. 2006 Nov 15;312(19):3701-10. doi: 10.1016/j.yexcr.2006.08.030. Epub 2006 Sep 9.
8
Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas.
Cancer Res. 2006 Jul 15;66(14):6936-46. doi: 10.1158/0008-5472.CAN-05-4578.
9
Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Cancer Res. 2006 May 1;66(9):4742-9. doi: 10.1158/0008-5472.CAN-05-4292.
10
Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group.
J Mol Diagn. 2006 May;8(2):202-8. doi: 10.2353/jmoldx.2006.050124.
Zotero 插件